SEE THE SCAN FROM A REAL DUPIXENT PATIENT
Click and drag
to see results

CT scan of patient from clinical trial. Individual results may vary.

Decreased sinus opacification as measured by LMK-CT score1,2

Week 24

(Key secondary
endpoint)2

27%Significant
IMPROVEMENT
with DUPIXENT
VS
1%IMPROVEMENT
with placebo

(P<0.0001)2,b

Week 52

(Other secondary
endpoint)2

38%Continued
IMPROVEMENT
with DUPIXENT
VS
2%WORSENING
with placebo2,c

Analysis was not multiplicity controlled. Results are descriptive.2

Data for Week 52: mean % change vs baseline.2

DUPIXENT DEMONSTRATED SUBSTANTIAL REDUCTIONS IN
OPACIFICATION ACROSS ALL INDIVIDUAL SINUSES AT WEEK 242

b Week 24 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -5.13 (95% CI: -5.80, -4.46)
(-5.21 from a baseline score of 18.12 vs -0.09 from a baseline score of 17.65, respectively) (P<0.0001).2

c Week 52 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -6.94 (95% CI: -7.87, -6.01) (-6.83 from a
baseline score of 18.42 vs 0.11 from a baseline score of 17.65, respectively).2

Lund-Mackay computed tomography (LMK-CT) score (range 0 to 24): reduced score indicates improvement.1

INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.